TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24969648

Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (n=84)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Nebulised 6% hypertonic saline (n=83)
Number of subjects: 292

Group type: COMPARATOR
Intervention: 0.9% normal saline (n=80)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: All groups (3%, 6%, and 0.9% saline)
Number of subjects: 292
Study: 22700039

Group type: EXPERIMENTAL
Intervention: Galantamine (GAL) 8 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21029662

Group type: EXPERIMENTAL
Intervention: rhTNFR:Fc 0.4 mg/kg, subcutaneously injected twice weekly
Number of subjects: 31

Group type: COMPARATOR
Intervention: MTX 10 mg × m(‐2) × w(‐1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: SASP 30‐50 mg × kg(‐1) × d(‐1) (for intolerance patients)
Number of subjects: 31
Study: 18347619

Group type: EXPERIMENTAL
Intervention: Eyelid hygiene regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics
Number of subjects: 0
Study: 16450078

Group type: EXPERIMENTAL
Intervention: Prolene mesh
Number of subjects: 600

Group type: COMPARATOR
Intervention: Vypro II mesh
Number of subjects: 600
Study: 12856976

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 80
Study: 10559091

Group type: EXPERIMENTAL
Intervention: 400 microg/d HFA-BDP
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: 800 microg/d CFC-BDP
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 8934215

Group type: EXPERIMENTAL
Intervention: Oral glucose administration (75 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PST, 120 mg)
Number of subjects: 10
Study: 6336781

Group type: EXPERIMENTAL
Intervention: TMP/SMX + E
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 31542391

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg and Quercetin 1000 mg for 3 days
Number of subjects: 9
Study: 29595449

Group type: EXPERIMENTAL
Intervention: Continuous oxygen (3 l/min if baseline oxygen saturation ≤ 93%, 2 l/min if > 93%) for 72 hours after randomisation
Number of subjects: 8003

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen (same flow rates as continuous) for three consecutive nights
Number of subjects: 8003

Group type: COMPARATOR
Intervention: Control (no routine oxygen supplementation unless required for reasons other than stroke)
Number of subjects: 8003
Study: 27471803

Group type: EXPERIMENTAL
Intervention: Zoom2 25% HP with UV light
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Beaming White 36% HP with LED light
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 25199313

Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg x kg(‐1))
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg x kg(‐1)) plus Cooling
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control (no prophylactic intervention)
Number of subjects: 226
Study: 22302296

Group type: EXPERIMENTAL
Intervention: 0.3 mg NTG skin spray
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 10
Study: 20363999

Group type: EXPERIMENTAL
Intervention: CO(2) therapy in addition to routine methods (surgical and/or chemical debridement, advanced dressings)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine methods alone (surgical and/or chemical debridement, advanced dressings)
Number of subjects: 70
Study: 17302075

Group type: EXPERIMENTAL
Intervention: Anesthetic gas extractor
Number of subjects: 24

Group type: COMPARATOR
Intervention: No extractor
Number of subjects: 24
Study: 14578611

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pravastatin (10 mg/day)
Number of subjects: 17
Study: 10732656

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg b.i.d. (increased to 75 mg b.i.d. from day 15)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Sertraline 50 mg once daily (remained at 50 mg b.i.d. from day 15)
Number of subjects: 147
Study: 8887985

Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) depletion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (1/4 strength preparation of an amino acid mixture)
Number of subjects: 7
Study: 1396891

Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 3964710

Group type: EXPERIMENTAL
Intervention: Diltiazem and propranolol (120 mg diltiazem and 160 mg propranolol)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem and propranolol
Number of subjects: 15
Study: 31765046

Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg) for 8 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks (treatment-experienced)
Number of subjects: 117
Study: 31675351

Group type: EXPERIMENTAL
Intervention: Occipital cryoneurolysis
Number of subjects: 52

Group type: COMPARATOR
Intervention: Corticosteroid (1 mL methylprednisolone 40 mg/mL) + local anaesthetic (1 mL bupivacaine 5 mg/mL)
Number of subjects: 52
Study: 28492701

Group type: EXPERIMENTAL
Intervention: Short-term intensive training (SIT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 49
Study: 26330583

Group type: EXPERIMENTAL
Intervention: Metal-on-metal (MoM) bearing surface
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metal-on-polyethylene (MoP) bearing surface
Number of subjects: 45
Study: 23756080

Group type: EXPERIMENTAL
Intervention: 1-second benzocaine spray before upper endoscopy
Number of subjects: 401

Group type: COMPARATOR
Intervention: No spray (control group)
Number of subjects: 401
Study: 21629111

Group type: EXPERIMENTAL
Intervention: Topical negative pressure therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional dressing therapy with sodium hypochlorite
Number of subjects: 24
Study: 19793724

Group type: EXPERIMENTAL
Intervention: Intravenous diamorphine (0.1 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intranasal diamorphine (0.1 mg/kg)
Number of subjects: 24
Study: 16966534

Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 to 6 mg/day)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 157
Study: 15376499

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment
Number of subjects: 0
Study: 11576376

Group type: EXPERIMENTAL
Intervention: rhGH (0.125 IU/kg for the first four weeks, then 0.25 IU/kg) three times a week after each dialysis session
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9701294

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hydrocodone-acetaminophen (5 mg hydrocodone with 500 mg acetaminophen)
Number of subjects: 68
Study: 8181137

Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 2597854

Group type: EXPERIMENTAL
Intervention: Behavioural family intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short educational programme or routine treatment (Control)
Number of subjects: 0
Study: 52767

Group type: EXPERIMENTAL
Intervention: 5 cm of positive end-expiratory pressure (P.E.E.P.)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No P.E.E.P.
Number of subjects: 25
Study: 30281141

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment followed by topical application of sodium stibogluconate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intralesional injections of sodium stibogluconate
Number of subjects: 20
Study: 28506006

Group type: EXPERIMENTAL
Intervention: Backpack load of 10% body weight (BW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Backpack load of 15% body weight (BW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No backpack load
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Backpack load of 5% body weight (BW)
Number of subjects: 30
Study: 26137916

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24100091

Group type: EXPERIMENTAL
Intervention: Web-based decision aid (n=124), used by 38.7% (48/124) of patients, with full functionality utilized by most users.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Care as usual (control group, n=126).
Number of subjects: 250
Study: 21447654

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tyramine infusion during exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined ATP and tyramine infusions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acetylcholine
Number of subjects: 20
Study: 18331374

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (400 ml, 12.5%) with paracetamol 1.5 g
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 25
Study: 16861254

Group type: EXPERIMENTAL
Intervention: Community hospital care
Number of subjects: 220

Group type: COMPARATOR
Intervention: District general hospital care
Number of subjects: 220
Study: 12742329

Group type: EXPERIMENTAL
Intervention: Aggressive management
Number of subjects: 694

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 694
Study: 11410122

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (AM) infusion (4 pmol.min(‐1).kg(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (vehicle - hemaccel)
Number of subjects: 7
Study: 9390695

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs and nonpharmacologic treatments
Number of subjects: 0
Study: 8430049

Group type: EXPERIMENTAL
Intervention: Buccal delivery of diclofenac sodium from a prototype hydrogel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (i.v.) infusion of diclofenac sodium
Number of subjects: 0
Study: 3168444

Group type: EXPERIMENTAL
Intervention: Full breastfeeding with high nursing frequency (8+ suckling episodes per 24 h)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Supplementation (11% by end of 3rd month, 48% by end of 6th month)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: High nursing frequency
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Age and parity
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Maternal weight, ponderal index, infant sex, birth weight, growth rate
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Full breastfeeding with high nursing frequency
Number of subjects: 676
Study: 29447248

Group type: EXPERIMENTAL
Intervention: Supported park prescription (physician counseling, maps, journal, pedometer, phone and text reminders, three weekly family nature outings with free transportation, food, and programming)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Independent park prescription (physician counseling, maps, journal, pedometer)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Park visits per week (self-reported and journaling)
Number of subjects: 78
Study: 28281728

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR) measurement
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Visual assessment by observer O1
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Visual assessment by observer O2
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Visual assessment by observer O3
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Comparison of FFR results to observers' decisions
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Kappa analysis for agreement between observers and FFR
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Kappa agreement analysis between observers
Number of subjects: 359
Study: 25287298

Group type: EXPERIMENTAL
Intervention: Together at School intervention program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 79
Study: 23176318

Group type: EXPERIMENTAL
Intervention: Physiotherapy eSkills Training Online resource
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual teaching only
Number of subjects: 0
Study: 19910619

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg before TKA and 150-50 mg twice daily for 14 days after TKA)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 18303706

Group type: EXPERIMENTAL
Intervention: Contingent reinforcement (CR)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CR plus nicotine patch (21 mg, CR+NRT) for 16 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Minimal intervention, self‐quit control group
Number of subjects: 181
Study: 16227041

Group type: EXPERIMENTAL
Intervention: Afternoon exercise session on a treadmill
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sedentary day
Number of subjects: 50
Study: 12004315

Group type: EXPERIMENTAL
Intervention: 308-nm xenon-chloride excimer laser, treated 3 times a week for a maximum of 12 treatments
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated control patches
Number of subjects: 18
Study: 10207634

Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin per day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablet for 3 months (washout period)
Number of subjects: 0
Study: 7829623

Group type: EXPERIMENTAL
Intervention: 100 micrograms potassium iodide (KI)/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 100 micrograms iodide plus 100 micrograms L‐T4/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 2199628

Group type: EXPERIMENTAL
Intervention: Aztreonam (2 g i.m.)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (4 ml lidocaine 2%)
Number of subjects: 162
Study: 435015

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 5

Group type: COMPARATOR
Intervention: Lithium carbonate
Number of subjects: 5
Study: 31129372

Group type: EXPERIMENTAL
Intervention: SHHC‐2.0 curriculum (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 0
Study: 28097016

Group type: EXPERIMENTAL
Intervention: Training intervention in community pharmacies
Number of subjects: 621

Group type: COMPARATOR
Intervention: Usual practice in community pharmacies
Number of subjects: 621
Study: 25558983

Group type: EXPERIMENTAL
Intervention: s.c. fentanyl
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: i.n. fentanyl
Number of subjects: 156

Group type: COMPARATOR
Intervention: i.m. pethidine
Number of subjects: 156
Study: 23051740

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) combination
Number of subjects: 1164

Group type: COMPARATOR
Intervention: High-dose angiotensin II receptor blocker (ARB)
Number of subjects: 1164
Study: 21887284

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 42418

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 42418
Study: 19087077

Group type: EXPERIMENTAL
Intervention: H Pipelle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pipelle
Number of subjects: 60
Study: 17893454

Group type: EXPERIMENTAL
Intervention: Fiberoptic intubation with a flexible silicone tube without neuromuscular blocking agents
Number of subjects: 270

Group type: COMPARATOR
Intervention: Orotracheal intubation with a polyvinyl chloride tube after induction with neuromuscular blocking agents
Number of subjects: 270

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 270
Study: 16322373

Group type: EXPERIMENTAL
Intervention: Progressive cardiovascular stress (PCS) protocol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active gravitational training (with bicycle work)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Passive gravitational training (without work)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PCS exposure
Number of subjects: 26
Study: 12846708

Group type: EXPERIMENTAL
Intervention: Neostigmine 10 microgram.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine 20 microgram.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine 30 microgram.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 microgram.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine 50 microgram.kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: No caudal block (group C)
Number of subjects: 120
Study: 10329078

Group type: EXPERIMENTAL
Intervention: Dalteparin (low molecular weight heparin)
Number of subjects: 293
Study: 8952122

Group type: EXPERIMENTAL
Intervention: Specific subtype of social phobia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generalized subtype of social phobia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social phobics with comorbid disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social phobics without comorbid disorders
Number of subjects: 0
Study: 1826285

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6803977

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (1 mg/kg or 4 mg/kg either by mouth or intramuscularly)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 46
Study: 30900581

Group type: EXPERIMENTAL
Intervention: AL‐Scan
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lenstar LS900
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Galilei
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrasound Pachymetry (UP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: AL‐Scan vs UP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lenstar LS900 vs UP
Number of subjects: 80

Group type: COMPARATOR
Intervention: AL‐Scan vs Lenstar LS900
Number of subjects: 80

Group type: COMPARATOR
Intervention: Galilei vs other methods
Number of subjects: 80
Study: 28144797

Group type: EXPERIMENTAL
Intervention: Self-explanation of pathophysiological mechanisms (n=20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No self-explanation (n=19)
Number of subjects: 39
Study: 25774995

Group type: EXPERIMENTAL
Intervention: Incongruent selective attention items
Number of subjects: 0

Group type: COMPARATOR
Intervention: Congruent selective attention items
Number of subjects: 0
Study: 23462262

Group type: EXPERIMENTAL
Intervention: Cefazolin 4 g before skin incision and 2 g during skin closure
Number of subjects: 8
Study: 22039966

Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplement
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 18270356

Group type: EXPERIMENTAL
Intervention: 4 cycles of etoposide and cisplatin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 3 cycles of cisplatin, etoposide, and bleomycin
Number of subjects: 186

Group type: COMPARATOR
Intervention: 4 cycles of bleomycin, etoposide, and cisplatin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (second- and third-line programs)
Number of subjects: 186
Study: 15987880

Group type: EXPERIMENTAL
Intervention: Relational encoding of word stimuli prior to recency judgements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Item-based processing of word stimuli prior to recency judgements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition of individual words (familiarity/recency judgements)
Number of subjects: 0
Study: 12904425

Group type: EXPERIMENTAL
Intervention: PCR assay for identification of Staphylococcus aureus and determination of methicillin resistance
Number of subjects: 28

Group type: COMPARATOR
Intervention: Empirical therapy
Number of subjects: 28
Study: 10671850

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 10 mg made up to 2 ml with saline
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketorolac with venous occlusion for 2 min
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 90
Study: 9115060

Group type: EXPERIMENTAL
Intervention: Coadministration of cyclosporine and diclofenac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration of cyclosporine and NSAIDs (excluding diclofenac)
Number of subjects: 0
Study: 1490503

Group type: EXPERIMENTAL
Intervention: Madopar HBS
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Madopar capsules
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Conventional Madopar
Number of subjects: 18
Study: 3839263

Group type: EXPERIMENTAL
Intervention: Combined 5‐fluorouracil, doxorubicin, and mitomycin C (FAM)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Combined methotrexate, doxorubicin, cyclophosphamide, and lomustine (MACC)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Overall comparison of both regimens
Number of subjects: 186

Group type: COMPARATOR
Intervention: MACC in adenocarcinoma
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: FAM in squamous-cell carcinoma
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Toxicity comparison
Number of subjects: 186
Study: 29852851

Group type: COMPARATOR
Intervention: 3% saline (SAL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5M sodium lactate (LAC)
Number of subjects: 10
Study: 27021606

Group type: EXPERIMENTAL
Intervention: MPH ERCT 40 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: IR MPH 40 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 33
Study: 25328688

Group type: EXPERIMENTAL
Intervention: Join the Healthy Boat programme
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1943